Acquisition of Exclusive Manufacturing and Marketing Rights for DOTATOC

AsiaNet 54322

GARCHING, Germany, Sep. 19, 2013 /PRN=KYODO JBN/ --

    - In-licensing of superior DOTA-Tyr3-octreotide

    - Pharmaceutical developmentfor treatment of NETs

    - Excellent pharmacokinetic properties

    ITM Isotope Technologies Munich AG (ITM) today announced that it has

entered into an exclusive licensing agreement with Progenics Pharmaceuticals

Inc. for pharmaceutical development and commercialization of radiolabeled

DOTA-conjugated somatostatin analogue DOTA-[Tyr3]-octreotide (DOTATOC known as

Edotreotide) for human oncology therapeutic use. Radiolabeled DOTATOC is a

superior agent for safe and highly effective radionuclide therapy of

somatostatin receptor positive tumors which offers excellent pharmacokinetic

properties and highest affinity to somatostatin receptor subtypes 2 and 5.

    Scope of license agreement

    The sublicense granted by Progenics Pharmaceuticals Inc. covers exclusive

worldwide manufacturing and marketing rights of DOTATOC and certain

radiolabeled DOTATOC for human oncology therapeutic use except the countries

Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait,

Lebanon, Oman, Qatar, Romania, Saudi Arabia, Syria, Turkey and United Arab

Emirates. Further terms of the agreement were not disclosed.

    Pharmaceutical development

    ITM affiliate ITG Isotope Technologies Garching GmbH will develop

radiolabeled DOTATOC for treatment of metastatic neuroendocrine tumors. In

addition, DOTATOC as precursor is now available and will be distributed in GMP

quality in cooperation with a leading supplier of advanced chemicals for

nuclear medicine.

    About DOTATOC

    DOTATOC or Edotreotide is a superior synthetic somatostatin analog which

binds perfectly to somatostatin receptors predominantly overexpressed in

neuroendocrine tumors (NETs). NETs are rare kind of tumors which arise from

neuroendocrine cells and may occur in different parts of the body.

    DOTA-chelated peptide Edotreotide exhibits excellent pharmacokinetic

properties and can be efficiently radiolabeled with medical radionuclides. Its

excellent therapeutic properties have been successfully started in various

clinical trials.

    About ITM Isotope Technologies Munich AG

    The itm Group is the leading company for the development, production and

worldwide distribution of highly effective radionuclides for diagnosis and

therapy as well as radionuclide-based medical devices. Its commitment to

shaping the future of theranostics is built on robust platform technologies and

innovative new generation radioisotopes which assure safety, performance and

security of supply!

    CONTACT: Christopher Morin

             Manager

             Marketing & Corporate Communications

             Phone: +49-89-289-13915

             Mail: Christopher.Morin@itg-garching.de

             Steffen Schuster

             CEO

             Phone: +49-89-289-13970

             Mail: Steffen.Schuster@itm.ag

             ITM Isotope Technologies Munich AG

             Aufsichtsratsvorsitzender - Udo J. Vetter

             Vorstandsvorsitzender - Steffen Schuster

             Sitz der Gesellschaft

             Lichtenbergstr. 1, 85748 Garching - HG Muenchen - HRB 154944

    SOURCE: ITM Isotope Technologies Munich AG